Inhibikase Therapeutics ( Inhibikase Therapeutics)

Primary tabs

Inhibikase Therapeutics's picture

Management

Contact Address

About Inhibikase Therapeutics

Founded in 2008, Inhibikase Therapeutics is a private biopharmaceutical company developing novel, small-molecule compounds to treat bacterial, viral, fungal and parasitic diseases through a common mechanism of action, often involving a single drug. Its pipeline of validated targets treat diseases therapeutically and prophylactically.

Inhibikase Therapeutics press release, blog etc

Mon, 06/17/2024 - 12:04 Inhibikase Therapeutics Completes Enrollment of the Phase 2 201 Trial Evaluating Risvodetinib in Untreated Parkinsons Disease
Wed, 06/05/2024 - 11:22 Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
Tue, 05/21/2024 - 06:17 Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
Wed, 05/15/2024 - 11:13 Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
Fri, 05/10/2024 - 04:58 Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Thu, 02/29/2024 - 03:52 Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Wed, 02/07/2024 - 17:48 Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
Thu, 02/01/2024 - 13:32 Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Fri, 01/19/2024 - 13:52 Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
Mon, 12/12/2022 - 12:59 Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro
Tue, 11/22/2022 - 08:57 Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
Fri, 08/26/2022 - 16:15 Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Tue, 08/23/2022 - 06:01 Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
Mon, 06/13/2022 - 05:10 Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review
Thu, 04/21/2022 - 16:28 Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
Wed, 04/06/2022 - 01:18 Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022
Thu, 03/31/2022 - 02:40 Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity
Fri, 03/25/2022 - 11:23 Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022

InfoBox